First, in baseline tumor biopsies from advanced renal cell carcinoma patients (n = 886; NCT02684006) (Choueiri et al., 2020; Motzer et al., 2020), the CD14CTX gene signature correlated with worse progression-free survival in patients treated with avelumab (anti-PD-L1)-based treatment compared with patients whose tumors had a lower CD14CTX gene signature (10.3 versus 12.5 months) (Figure 4H). Here, CD274 is linked to renal cell carcinoma.